NOT-DA-04-023: ANIMAL MODELS OF METHAMPHETAMINE-INDUCED COGNITIVE IMPAIRMENT

Department of Health
and Human Services (HHS)
NIH... Turning Discovery Into Health^®

ANIMAL MODELS OF METHAMPHETAMINE-INDUCED COGNITIVE IMPAIRMENT

RELEASE DATE:  February 24, 2004

RFP AVAILABLE:  N01DA-4-8849

NOTICE:  NOT-DA-04-023

National Institute on Drug Abuse (NIDA)

The National Institute on Drug Abuse (NIDA) plans to solicit proposals 
from qualified organizations having in-house capability to perform in 
vivo rodent behavioral pharmacology studies of potential 
pharmacotherapies for the cognitive impairment seen in methamphetamine 
dependence.  In brief, the objectives of this project are: (1) To 
establish and validate animal model(s) of the cognitive impairment 
experienced by methamphetamine use; (2) To evaluate compounds for their 
potential ability to treat methamphetamine-induced cognitive deficits; 
(3) To evaluate compounds for their potential to exacerbate 
methamphetamine-induced cognitive deficits; and, (4) To evaluate the 
potential of compounds to produce methamphetamine-like effects on 
cognition. The offerors must propose the models to be developed and 
utilized for compound testing. The identity of proprietary test 
compounds will be blinded, and the resulting data will be utilized by 
the NIDA Medications Development Program.  In order to handle 
substances under the Controlled Substances Act of 1970, it is mandatory 
that offerors possess a DEA Research Registration for Schedules II to V 
and demonstrate the capability to obtain a DEA registration for 
Schedule I controlled substances.  All offerors must comply with NIH 
guidelines on the care and use of laboratory animals 
(http://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf).  
We anticipate the award of one cost reimbursement contract for a base 
period of three years.  The contract will include two 1-year options as 
well as additional quantity options.  RFP No. N01DA-4-8849 will be 
available electronically on or about March 9, 2004.  You will access 
the RFP through the FedBizOpps (URL: http://www.fedbizopps.gov) or 
through the NIDA website: (URL: 
http://www.nida.nih.gov/RFP/RFPList.html). Please note that NIDA uses a 
streamlined RFP format which includes only the Work Statement, 
Deliverables, Reporting Requirements, Special Requirements, Mandatory 
Qualifications, Technical Evaluation Criteria, and other necessary 
Proposal Preparation Instructions. All information required for the 
submission of a proposal is contained in or accessible through the 
streamlined RFP package. Response to the RFP will be due on or about 
May 17, 2004.  NIDA will consider proposals submitted by any 
responsible offeror.  This advertisement does not commit the Government 
to award a contract.

Point of Contact:

Kenneth E. Goodling, Contracting Officer
National Institute on Drug Abuse, NIH
Contracts Management Branch, OPRM
6101 Executive Blvd., Room 260, MSC 8402
Bethesda, Maryland  20892-8402
E-mail: [email protected]
Telephone: (301) 443-6677
Fax:  (301) 443-7595
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices